We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New AI Algorithms Enable Diagnosis of Difficult Cancers

By LabMedica International staff writers
Posted on 07 Dec 2023
Print article
Image: New AI algorithms can aid diagnosis of clinically difficult-to-interpret cancerous tumors (Photo courtesy of CLARIFY)
Image: New AI algorithms can aid diagnosis of clinically difficult-to-interpret cancerous tumors (Photo courtesy of CLARIFY)

A team of European researchers and companies, led by the Valencia Polytechnic University (UPV, Valencia, Spain), through the CVBLab-HUMAN-tech group, has developed novel artificial intelligence (AI) algorithms to aid the diagnosis and treatment of cancerous tumors that are difficult to interpret clinically. This is one of the main results of the CLARIFY project, which is now in its final months of execution.

CLARIFY is an innovative, multinational, multi-sectorial, and multidisciplinary research initiative with a focus on developing a robust automated digital diagnostic environment based on AI and cloud-oriented data algorithms. The goal is to streamline the interpretation and diagnosis of whole-slide-images (WSIs) globally, to optimize the advantages of digital pathology, and to support pathologists in their routine tasks. The project has concentrated on specific and difficult-to-diagnose cancer types to evaluate the effectiveness of the tools and methods it has developed. These include Triple Negative Breast Cancer (TNBC), High-risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC), and Spitzoid Melanocytic Lesions (SML), representing the diverse challenges present in cancer diagnosis.

Furthermore, the CLARIFY project has yielded additional noteworthy results, such as the creation of comprehensive databases for the studied cancers. These databases are poised to be valuable assets for the medical and scientific communities. The project has also made progress in the secure handling of data in cloud environments, addressing the unique requirements of the healthcare sector. This includes several practical applications within the project's framework, enhancing data security and management.

“In all three cases, the diagnosis is complex and challenging, which we are already addressing with this project,” said Valery Naranjo, project leader. “With these algorithms, we are taking another step forward in facilitating the interpretation of histological images and, ultimately, the diagnosis of these types of cancer for medical professionals.”

Related Links:
Valencia Polytechnic University

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.